Press Releases September 25, 2026 06:00 AM

VEON Capital Markets Day 2026

VEON Announces Capital Markets Day for November 16, 2026, at Nasdaq MarketSite

By Derek Hwang
Share
Twitter Reddit Facebook LinkedIn
VEON

VEON Ltd., a Nasdaq-listed global digital operator, announced its upcoming Capital Markets Day event to be held on November 16, 2026, in New York City. The event will include presentations on VEON's strategic priorities, business performance, outlook, and long-term value creation. Investors and analysts can attend in person or virtually via webcast.

VEON Capital Markets Day 2026
VEON
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • VEON operates in five countries with over 150 million connectivity users and more than 205 million digital users, highlighting its large market reach in emerging markets.
  • The Capital Markets Day event aims to communicate VEON's strategic vision and outlook to investors and analysts, enhancing transparency and engagement.
  • The event offers both in-person and virtual attendance options, reflecting accessibility and investor outreach efforts.

Event and Registration Details

Dubai and New York, September 25, 2026 – VEON Ltd. (Nasdaq: VEON), a global digital operator (“VEON” or “the Company”), today announces registration details for its Capital Markets Day, to be held on Monday, November 16, 2026, at the Nasdaq MarketSite in New York City.

The event will begin promptly at 11:00 ET and will feature presentations from VEON’s senior management on the Company’s strategic priorities, business performance, outlook and approach to long-term value creation. Participants are invited to attend in person or join virtually via webcast.

In-person attendance

Nasdaq MarketSite
151 West 43rd Street, 10th Floor, Times Square, New York, NY 10036
Monday, November 16, 2026, 11:00 ET.

Attendees should arrive by 10:30 ET to allow time for registration and security checks.

In-person attendance at the Capital Markets Day is subject to prior registration and confirmation. Investors and analysts wishing to attend in person may email to [email protected]. Participants are encouraged to register at their earliest convenience and no later than Friday, November 6, 2026. Confirmed attendees will be required to present a valid photo ID upon arrival.

Registration details will be shared with Nasdaq for access coordination. Registered attendees will receive a separate Nasdaq access link approximately 24 hours before the event with instructions for ID registration, verification, and building entry. Attendees must complete these steps in advance and bring valid government-issued photo ID for entry.

Virtual participation

Virtual participants are required to register for the event via the webcast link provided: https://brrmedia.news/VEON_CMD_2026

A webcast replay and related presentation materials will be available on VEON’s investor relations website after the event.

About VEON
VEON is a digital operator that provides connectivity and digital services over 150 million connectivity and more than 205 million digital users. Operating across five countries that are home to more than 6% of the world’s population, VEON is transforming lives through technology-driven services that empower individuals and drive economic growth. VEON is listed on NASDAQ. For more information, visit: https://www.veon.com.

Contact information
VEON
Investor Relations
[email protected]


Risks

  • The article does not specify any new strategic initiatives or financial guidance updates, which may lead to uncertainty about near-term growth prospects impacting investor sentiment.
  • As VEON operates across emerging markets, it faces typical risks from economic, political, and regulatory volatility in these regions affecting operational performance.
  • The lack of detailed financial data or projections in the announcement could limit investors' ability to assess the company's future performance, potentially affecting market response.

More from Press Releases

Edible Garden Wins Third New Walmart Fresh Herb Distribution Center Award, Accelerating Expansion Across the Eastern Midwest Sep 25, 2026 Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa Sep 25, 2026 C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting Sep 25, 2026 FactSet Appoints Marcel Prins to Board of Directors Sep 25, 2026 Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN Sep 25, 2026